A Study Comparing PEG-3350 (Miralax) and Gatorade With PEG-ELS (Golytely) for Bowel Preparation Prior to Colonoscopy
NCT ID: NCT01028573
Last Updated: 2012-03-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
400 participants
INTERVENTIONAL
2009-11-30
2012-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Miralax (PEG 3350) vs. Golytely as Bowel Preparation for Screening Colonoscopy
NCT01170754
A Comparison of 5 Low Volume Bowel Preparations
NCT01719653
A Trial Comparing Bowel Preparation and Patient Tolerability of Miralax Versus Golytely
NCT00889655
Gatorade/Miralax With or Without Bisacodyl Versus NuLytely for Colonoscopy Preparation
NCT01063049
A Trial Comparing Split-Dose Miralax With Amitiza Pretreatment Versus Dulcolax Pretreatment Versus Golytely for Bowel Cleansing Prior to Colonoscopy
NCT00953017
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
DIAGNOSTIC
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group 1
4L of PEG-ELS (Golytely) consumed on the evening before colonoscopy
PEG-ELS (Golytely)
4L consumed evening before colonoscopy
Group 2
2L of PEG-ELS (Golytely) consumed on the evening before and 2L consumed on the morning of colonoscopy
PEG-ELS (Golytely)
2L consumed on the evening before and 2L consumed on the morning of Colonoscopy
Group 3
238g of PEG-3350 mixed with 2L of Gatorade
Miralax mixed with Gatorade
238g of PEG-3350 (Miralax) mixed with 2L of Gatorade consumed on the evening before colonoscopy
Group 4
1L of PEG-3350 + Gatorade
Miralax
1L of PEG-3350 + Gatorade consumed on the evening before and 1L of PEG-3350 + Gatorade consumed on the morning of Colonoscopy
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
PEG-ELS (Golytely)
4L consumed evening before colonoscopy
PEG-ELS (Golytely)
2L consumed on the evening before and 2L consumed on the morning of Colonoscopy
Miralax mixed with Gatorade
238g of PEG-3350 (Miralax) mixed with 2L of Gatorade consumed on the evening before colonoscopy
Miralax
1L of PEG-3350 + Gatorade consumed on the evening before and 1L of PEG-3350 + Gatorade consumed on the morning of Colonoscopy
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Undergoing full colonoscopy for colorectal cancer screening or colon polyp/cancer surveillance or other diagnostic purpose
Exclusion Criteria
* Pregnant or lactating
* Baseline abnormalities of relevant serum electrolytes including Sodium, Potassium, Calcium, Magnesium and phosphorus
* Congestive Heart Failure NY Heart Assn, Grades III and IV
* Liver Cirrhosis Childs Pugh Class B or C
* Serum Creatinine greater than 1.5
* Previous alimentary tract surgery
* Ongoing symptoms of abdominal pain, bloating, nausea or constipation
* Ileus, suspected bowel obstruction, toxic colitis or megacolon, severe ulcerative colitis
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Southern California Institute for Research and Education
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
VA Long Beach Healthcare System
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Mazen Jamal, MD
Role: PRINCIPAL_INVESTIGATOR
VA Long Beach Healthcare System
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
VA Long Beach Healthcare System
Long Beach, California, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
976
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.